ARCHIVES

XGEVA not Inferior to Zometa In 1,776-Patient Phase III Study

This article is from The Cancer Letter archive.

Vol. 34 No. 3 | March 25, 2011

Download PDF Visit The Full Archive

Related Articles

FDA Approvals: Lymphoseek Label Updated to Include Head and Neck SCC

June 27, 2014

Standard Procedures Discarded in Review Of $20 Million in Texas Funds For Project Led by Wife of MD Anderson President

May 25, 2012

Nine More state To Pay For Cancer Treatment Of CDC-Screened Women.

September 7, 2001

AACR Presents Awards At Annual Meeting

April 23, 2010

Stand Up To Cancer Selects Five Groups For “Dream Team” Grants Totaling $73.6M.

May 29, 2009

With $10.4 Billion To Spend In 18 Months, NIH Says Money Will Be Spent Rationally. Funds Will Support R01s

February 20, 2009